Overview

* Cibus ( CBUS ) Q3 revenue misses analyst expectations, reporting $615,000 compared to $1.39 mln estimate

* Net loss for Q3 was $24.3 mln, significantly lower than $201.5 mln last year

* Company focuses on strategic partnerships and cost reductions to support future growth

Outlook

* Cibus ( CBUS ) targets initial commercial launch of rice traits in Latin America by 2027

* Company plans commercial expansion of Sustainable Ingredients program in 2026

* Cibus ( CBUS ) aims to reduce annual net cash usage to $30 mln by 2026

Result Drivers

* LATAM EXPANSION - Cibus ( CBUS ) continues to progress with herbicide tolerance traits in Rice, targeting initial commercial launches in Latin America by 2027

* INDIA MARKET ENTRY - Cibus ( CBUS ) engaged AgVayā to support entry into Indian market for advanced gene editing solutions

* BIOFRAGRANCE PILOT - Successfully completed pre-commercial pilot runs for biofragrance products, targeting commercial expansion in 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $615,000 $1.39

Revenue mln (3

Analysts

)

Q3 EPS -$0.44

Q3 Net -$24.30

Income mln

Q3 -$15.44

Income mln

from

Operatio

ns

Q3 $16.05

Operatin mln

g

Expenses

Q3 -$24.31

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Cibus Inc ( CBUS ) is $15.50, about 91.3% above its November 12 closing price of $1.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)